Abstract
The European Society for Medical Oncology (ESMO) and the European Organisation for Research and Treatment of Cancer (EORTC) welcome the adoption of the Clinical Trials Regulation (CTR) by the European Union (EU) as a clear signal that the EU supports research while fully respecting patients' rights and safeguards. The CTR is a step in the right direction to correct years of serious challenges faced by researchers when performing clinical trials. However, there are still many unresolved issues that may yet take research efforts down the wrong path.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
